市況評論

作者

譚思聰先生 (Gary Tam)
輝立証券經理

現任輝立証券分行經理, 樂意為客戶提供投資股票策略及期權分析,對提高投資組合回報有豐富經驗, 歡迎各位來電交流心得。
電話:
3651 7381, 9378 2167

CSPC Pharma (1093)

2017年4月7日 星期五 觀看次數3092

Business Summary:

CSPC Pharma focuses on the manufacturing, researching and marketing of medicines and pharmaceutical related products. The group has three major business segments (consisting of nearly 1,000 finished drugs products) including innovative drugs 創新藥, common generic drugs 普藥and bulk drugs  原料藥.  The manufacturing facilities of CSPC are mainly located in Shijiazhuang City石家莊市, Hebei Province, China.

 

Innovative drugs are mainly used for the treatment of acute ischemic stroke腦中風,  cardio-cerebrovascular心腦血管, oncology抗腫瘤, digestive system, mild to moderate memory and mental impairment resulting from vascular dementia血管痴呆, senile dementia 老年呆症and brain trauma腦創傷.

Common generic drugs are mainly used for the treatment for anti-inflammatory抗炎, antipyretic analgesic解熱鎮痛, fever, cold, cough and various types of infection caused by bacteria. Drugs also include traditional Chinese medicine.

 

Bulk drugs products include antibiotics, vitamin C and caffeine series咖啡因系列.

 

Business Summary and Prospect:

For the last year as of the end of December, net profit rose 26.2% yearly to HK$2.10 billion versus HK$1.67 billion. Sales revenue increased 8.6% from HK$11.39 billion to HK$12.37 billion. Gross profit rose 20.8% to 6.31 billion, and operating profit before tax increased 24.8% to 2.64 billion. Net finance cost was 28.7 million which decreased by 38.3%. The earnings per share equaled HK$35.25 cents (versus Hk$28.18 cents previously) and a final dividend of HK$12 cents was declared.

 

UBS report said in China's newly announced National Drug Reimbursement List (NDRL), two of CSPC PHARMA's major drugs- NBP injection 恩必普注射液: 治療腦中風and Jinyouli (JYL) 津優力: 預防化療後的白細胞減少– are included; which are slightly better than expected. The inclusion could materially boost the two drugs' revenue growth from 2018. Moreover, CSPC's oncology drug, Duomeisu (DMS)多美素:治療骨髓腫瘤, could also be included in the coming list for price negotiation. It is expected that its revenue/earnings forecasts will be increased by 3%/8% for 2018 and 5%/12% for 2019. UBS lifted the target price from $9.5 to $11.1, implying 25x 2017 P/E estimate. The stock is still attractive following its strong rally in the past two months, and the broker keeps the rating Buy.

 

Risk:

a) relatively higher P.E. and P.B. compared with other pharmaceutical industry

b) Factory production is temporarily halted owing to anti-pollution drive (reduce the blanket of smog)

c) poor price negotiation and increasing cost for developing new drugs

d) poor sales performance than expected from Vitamin C

 

Technical Analysis:

The stock prices hit historic high of $10.7 on 5 Apr, 2017 after the announcement of final year-end result. It is suggested to accumulate buying when stock price is below $10. Strong fundamental support is found at $9.5; which is about 50-day moving average. The target price for medium term is $11. Cut- loss will be $9.0

 

 

References

www.hkex.com.hk

www.etnet.com.hk

www.afe-solutions.com

 

I, Gary Tam, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto.

 

研究報告由輝立証券集團旗下於香港證監會持牌的輝立証券(香港)有限公司及/ 或輝立商品有限公司(“輝立”)所發報。本文所包含的資料均為輝立從相信為準確的來源搜集。輝立對有關報告所引致之任何損失或虧損概不負責。本報告所載的資料只供参考用途,並沒有法律約束力,亦不構成投資建議、邀約、購入、出售任何產品。
投資涉及風險,有可能損失投資本金。你應諮詢專業人士,就本身的投資經驗、財務狀況、個人目標及風險取向,以提供投資意見。各類產品的風險,請參閱本公司網頁 http://www.phillip.com.hk《風險披露聲明》。
輝立(或其僱員) 可能持有本文所述有關的投資產品。此外,輝立(或任何附屬公司)隨時可能替向報告內容所述及的公司提供服務、招攬或業務往來。
以上資料為輝立擁有並受版權及知識產權法保護。除非事先得到輝立明確書面批准,否則不應複製、散播或發佈。
返回頁首
聯絡我們
請即聯絡你的客戶主任或致電我們。
研究部
電話 : (852) 2277 6846
傳真 : (852) 2277 6565
電郵 : businessenquiry@phillip.com.hk

查詢及支援
分行資料
查數網
登入
黃師傅每日講股
研究部快訊
免費訂閱
聯絡我們